Scancell gives positive update on melanoma treatment data

Biopharmaceutical company Scancell Holdings reported further encouraging results from the ongoing 'Phase 1/2' clinical trial of its melanoma treatment SCIB1, which it presented at the annual meeting of the American Society of Clinical Oncology in Chicago.

The data showed that all 16 patients with resected diseases are still alive, while survival times are “very encouraging.” If a disease is resected it means part or all of the tumour has been removed.

Only five patients have had a recurrence of the disease, with all other patients disease-free for between 27 and 46 months since they entered the study.

Professor Lindy Durrant, joint chief executive officer of Scancell and Professor of Cancer Immunotherapy at Nottingham Unversity said: “The on-going positive results from this Phase 1/2 trial gives us confidence that our SCIB1 ImmunoBody has the potential to become the first non-toxic effective adjuvant treatment for resected melanoma.”